Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
V Ambrosini, J Kunikowska, E Baudin, L Bodei… - European journal of …, 2021 - Elsevier
Nuclear medicine plays an increasingly important role in the management neuroendocrine
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …
neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission …
Future of theranostics: an outlook on precision oncology in nuclear medicine
T Langbein, WA Weber, M Eiber - Journal of Nuclear Medicine, 2019 - jnm.snmjournals.org
Molecular alterations in malignant disease result in the expression or upregulations of
various targets that can be used for imaging and treatment with radiopharmaceuticals. This …
various targets that can be used for imaging and treatment with radiopharmaceuticals. This …
Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms
Neuroendocrine neoplasms constitute a diverse group of tumors that derive from the
sensory and secretory neuroendocrine cells and predominantly arise within the pulmonary …
sensory and secretory neuroendocrine cells and predominantly arise within the pulmonary …
Somatostatin receptor PET ligands-the next generation for clinical practice
Somatostatin receptors (SSTRs) are variably expressed by a variety of malignancies. Using
radiolabeled somatostatin analogs (SSAs), the presence of SSTRs on tumor cells may be …
radiolabeled somatostatin analogs (SSAs), the presence of SSTRs on tumor cells may be …
The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
PE Harris, K Zhernosekov - Frontiers in Endocrinology, 2022 - frontiersin.org
Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …
New PET radiotracers for the imaging of neuroendocrine neoplasms
E Fortunati, G Argalia, L Zanoni, S Fanti… - … treatment options in …, 2022 - Springer
Opinion statement Neuroendocrine neoplasms (NEN) are a heterogeneous group of
tumours derived from cells of neuroendocrine origin and can potentially arise everywhere in …
tumours derived from cells of neuroendocrine origin and can potentially arise everywhere in …
[HTML][HTML] Overview of radiolabeled somatostatin analogs for cancer imaging and therapy
R Eychenne, C Bouvry, M Bourgeois, P Loyer… - Molecules, 2020 - mdpi.com
Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …
[HTML][HTML] Insight into the Development of PET Radiopharmaceuticals for Oncology
While the development of positron emission tomography (PET) radiopharmaceuticals
closely follows that of traditional drug development, there are several key considerations in …
closely follows that of traditional drug development, there are several key considerations in …
First-in-humans study of the SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms …
The objective of this study was to assess the safety, dosimetry, and efficacy of the 177Lu-
labeled somatostatin receptor (SSTR) antagonist DOTA-p-Cl-Phe-cyclo (d-Cys-Tyr-d-4 …
labeled somatostatin receptor (SSTR) antagonist DOTA-p-Cl-Phe-cyclo (d-Cys-Tyr-d-4 …
Neuroendocrine neoplasms of the small bowel and pancreas
The traditionally promulgated perspectives of neuroendocrine neoplasms (NEN) as rare,
indolent tumours are blunt and have been outdated for the last 2 decades. Clear increments …
indolent tumours are blunt and have been outdated for the last 2 decades. Clear increments …